Hostname: page-component-7b7567c8c-wxvwp Total loading time: 0 Render date: 2026-11-17T03:30:24.482Z Has data issue: false hasContentIssue false

Progressive Supranuclear Palsy

Published online by Cambridge University Press:  05 January 2016

Joseph Jankovic*
Affiliation:
Department of Neurology, Baylor College of Medicine, Houston, Texas
Haydee Rohaidy
Affiliation:
Department of Neurology, Baylor College of Medicine, Houston, Texas
*
Department of Neurology, Baylor College of Medicine, 1 Baylor Plaz, Houston, Texas 77030 U.S.A.
Rights & Permissions [Opens in a new window]

Abstract:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the 'Save PDF' action button.

Progressive supranuclear palsy (PSP) was first recognized as a distinct morbid entity by Richardson, Steele and Olszewski a quarter century ago. Subsequent experience has confirmed and extended their original observations. PSP has become familiar as a chronic progressive disorder with extrapyramidal rigidity, bradykinesia, gait impairment, bulbar palsy, dementia and a characteristic supranuclear ophthalmoplegia. It is an important cause of parkinsonism. Its etiology remains obscure. Familial concentrations have not been observed.

Some cases exhibit no oculomotor dysfunction. Dementia is usually mild. Recent neuropsychological studies have defined features consistent with frontal lobe cortical dysfunction. Seizures and paroxysmal EEG activity may occur.

CT and MRI scans show midbrain atrophy early and later atrophy of the pontine and midbrain tegmentum and the frontal and temporal lobes. PET scans have shown frontal hypometabolism and loss of striatal D-2 dopamine receptors. Postmortem studies have documented involvment of both dopaminergic and cholinergic systems. Treatment remains palliative and unsatisfactory.

Information

Type
Research Article
Copyright
Copyright © Canadian Neurological Sciences Federation 1987